Tomas Mlcoch

Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients

2020 | Lékařská fakulta v Plzni, 1. lékařská fakulta

Publikace